Development and Evaluation of a New Technological Way of Engaging Patients and Enhancing Understanding of Drug Tolerability in Early Clinical Development: PROACT
Conclusion
Overall, PROACT achieved proof of concept in this small pilot study and delivered a secure end-to-end system that protected patient privacy and provided preliminary insight into patient experiences beyond the usual clinical trial data set. The use of mobile devices to interact actively with participants in clinical trials may be a new way of engaging and empowering patients. Further validation of this technology in larger patient cohorts is ongoing.
Funding
AstraZeneca.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: AstraZeneca | Cancer & Oncology | Clinical Trials | Computers | Drugs & Pharmacology | Study